ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 With Potential for Effective Quarterly or Possibly Bi-Annual Dosing: Results of Single-Blind, Placebo-Controlled, Phase 1 Single-Ascending Dose (SAD), and Multi-Dose (MD) Trial in Adults With Elevated LDL-C, on and off Statins

Fitzgerald Kevin; Simon Amy; White Suellen; Borodovsky Anna; Patel Nirav; Bettencourt Brian; Clausen Valerie; Horton Jay D; Wijngaard Peter; Kauffman Robert; Kallend David

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 With Potential for Effective Quarterly or Possibly Bi-Annual Dosing: Results of Single-Blind, Placebo-Controlled, Phase 1 Single-Ascending Dose (SAD), and Multi-Dose (MD) Trial in Adults With Elevated LDL-C, on and off Statins

作者：Fitzgerald Kevin; Simon Amy; White Suellen; Borodovsky Anna; Patel Nirav; Bettencourt Brian; Clausen Valerie; Horton Jay D; Wijngaard Peter; Kauffman Robert; Kallend David

来源：Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium, 2015-11-15 to 2015-11-19.

Hyperlipidemia
Cardiovascular therapeutics
PCSK9
LDL

出版日期2015-12-8

收藏分享被引浏览

更新时间：2018-01-17 18:37

相似论文
引用论文
参考文献

ALN-PCSsc, an RNAi Investigational Agent That Inhibits PCSK9 With Potential for Effective Quarterly or Possibly Bi-Annual Dosing: Results of Single-Blind, Placebo-Controlled, Phase 1 Single-Ascending Dose (SAD), and Multi-Dose (MD) Trial in Adults With Elevated LDL-C, on and off Statins

产品服务

站内浏览

服务支持

联系方式

科研之友